.

New Drug Research and Development by iLeadBMS iLeadBMS

An Honest Company that Cares About People and the Future
  • Molecular Design Capabilities
  • Multi-Drug Targeting
  • Enhancing Development Success Rates
  • Collaborating with Global Best CROs

Pipeline

Updated: May 2024

      

iLeadBMS is innovative research-intensive pharma company with a robust globally competitive R&D pipeline

Fibrotic & Autoimmune Disease

Fibrotic & Autoimmune Disease

Oral available small molecule chemokine modulator for treatment of different fibrotic disease.

The lead candidate act as a chemokine agonist, demonstrating superior effects compared to reference drugs in both IPF lung models (prevention and therapeutic model) and CCl4-induced liver fibrosis models. Bleomycin induced skin fibrosis, kidney fibrosis, BDL liver fibrosis, PAH & Ischemia reperfusion (I/R) model is ongoing.

Oncology

Oncology

Oral available small molecule with potent anti-cancer activities for various types of cancer, presenting new possibilities for cancer treatment.

We discovered innovative drugs with potent anti-cancer activities, including a CDK 4/6/12 inhibitor for HER2-negative gastric cancer and selective molecules disrupting SOS1-KRAS interaction. Additionally, they have developed a novel degrader series and a molecular glue for treating various cancers.

Neurodegenerative Disease

Neurodegenerative Disease

Oral available small molecule offer new possibilities for potent BBB-permeable small molecules against a variety of neurodegenerative diseases.

Activation of CXCR7 can treat neurodegenerative diseases like ALS, MS, and Parkinson's by inducing anti-inflammatory A2 astrocytes and suppressing microglial activity through CXCL12 clearance. Additionally, inhibiting c-ABL prevents alpha-synuclein aggregation, and inhibiting NLRP3 activation reduces brain inflammation, offering promising treatment approaches.

Community